USFDA issues warning letter for Granules India Gagillapur plant, new product approvals to take a hit
The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted compliance issues. While existing operations continue, pending product reviews could be delayed. Granules India is implementing corrective measures and aims to resolve the matter promptly, maintaining product quality and safety without further FDA escalation.
The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted compliance issues. While existing operations continue, pending product reviews could be delayed. Granules India is implementing corrective measures and aims to resolve the matter promptly, maintaining product quality and safety without further FDA escalation.
